SeaStar’s SCD device was granted breakthrough device designation by the US Food and Drug Administration (FDA) in October 2023. Image credit: Shutterstock/Oleksandr Drypsiak.

SeaStar Medical is progressing its pivotal trial evaluating the use of its Selective Cytopheretic Device (SCD) in patients with acute kidney injury (AKI), with the company announcing that 12 patients have now been enrolled.

The NEUTRALISE-AKI pivotal clinical trial (NCT05758077) is expected to enrol up to 200 patients with AKI who require continuous kidney replacement therapy (CKRT).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

SeaStar Medical’s chief medical officer Kevin Chung said that the company has enrolled five patients over the past six weeks, as well as activating additional clinical sites, according to a 28 December press release.

There are 30 study sites in the US expected for the trial, as per ClinicalTrials.gov. Five of these are currently in the recruiting stage. The trial enrolled its first patient in June 2023.

SCD is a type of cell-directed extracorporeal therapy delivered via CKRT. It works by selectively targeting and neutralising neutrophils and monocytes – effector cells that play a key role in hyperinflammation. The neutralised cells are then returned back into the body through the blood.  Normally, the overactivity of the immune system can lead to organ damage and can even lead to multi-organ failure.

See Also:

SeaStar’s SCD device was granted breakthrough device designation by the US Food and Drug Administration (FDA) in October 2023.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company expects to receive FDA approval under a Humanitarian Device Exemption (HDE) for use in children weighing 10 kilograms or more with AKI and sepsis. Children with a septic condition requiring continuous CKRT anytime within the next 30 to 45 days will also be indicated. In October 2023, the company received correspondence from the FDA signalling the device to be approvable under HDE.

The device’s rollout is expected in Q1 2024, according to SeaStar.

The NEUTRALISE-AKI study’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with SCD. Patients receiving treatment with the SCD in addition to CKRT will be compared to patients in the control group only receiving CKRT standard of care. A subgroup analysis will also explore the potential effectiveness of SCD therapy in AKI patients with sepsis and acute respiratory distress syndrome.